GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NextGen Biomed Ltd (XTAE:NXGN) » Definitions » Enterprise Value

NextGen Biomed (XTAE:NXGN) Enterprise Value : ₪5.05 Mil (As of Jun. 06, 2024)


View and export this data going back to 2000. Start your Free Trial

What is NextGen Biomed Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, NextGen Biomed's Enterprise Value is ₪5.05 Mil. NextGen Biomed's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was ₪-8.99 Mil. Therefore, NextGen Biomed's EV-to-EBIT ratio for today is -0.56.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, NextGen Biomed's Enterprise Value is ₪5.05 Mil. NextGen Biomed's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was ₪-8.99 Mil. Therefore, NextGen Biomed's EV-to-EBITDA ratio for today is -0.56.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, NextGen Biomed's Enterprise Value is ₪5.05 Mil. NextGen Biomed's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was ₪0.00 Mil. Therefore, NextGen Biomed's EV-to-Revenue ratio for today is .


NextGen Biomed Enterprise Value Historical Data

The historical data trend for NextGen Biomed's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextGen Biomed Enterprise Value Chart

NextGen Biomed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Enterprise Value
Get a 7-Day Free Trial Premium Member Only 5.35 5.68 63.79 43.29 21.83

NextGen Biomed Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 122.35 43.29 22.25 21.83 18.90

Competitive Comparison of NextGen Biomed's Enterprise Value

For the Medical Instruments & Supplies subindustry, NextGen Biomed's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NextGen Biomed's Enterprise Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NextGen Biomed's Enterprise Value distribution charts can be found below:

* The bar in red indicates where NextGen Biomed's Enterprise Value falls into.



NextGen Biomed Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

NextGen Biomed's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as

NextGen Biomed's Enterprise Value for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NextGen Biomed  (XTAE:NXGN) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

NextGen Biomed's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=5.051/-8.991
=-0.56

NextGen Biomed's current Enterprise Value is ₪5.05 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. NextGen Biomed's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was ₪-8.99 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

NextGen Biomed's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=5.051/-8.986
=-0.56

NextGen Biomed's current Enterprise Value is ₪5.05 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. NextGen Biomed's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was ₪-8.99 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

NextGen Biomed's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=5.051/0
=

NextGen Biomed's current Enterprise Value is ₪5.05 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. NextGen Biomed's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was ₪0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NextGen Biomed Enterprise Value Related Terms

Thank you for viewing the detailed overview of NextGen Biomed's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


NextGen Biomed (XTAE:NXGN) Business Description

Traded in Other Exchanges
N/A
Address
Azrieli Center, Round Tower 22nd Floor, Tel Aviv, ISR, 6701101
NextGen Biomed Ltd is pharmaceutical company. It manufactures medical instruments. Its products include pain-free auto-injectors, lancet devices and personal use pain alleviators. It develops and markets medical equipments. Its product line include DPS-101, which is used for treatment for psoriasis. Its other product line include DPS-101 phase II/III is in clinical trial.